Pfizer (PFE) Total Non-Current Liabilities (2009 - 2026)

Pfizer (PFE) has reported Total Non-Current Liabilities for 18 consecutive years, with $100.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 2.22% year-over-year to $100.9 billion in Q2 2026; TTM through Jun 2026 was $100.9 billion, a 2.22% decrease from a year earlier, with the FY2025 full-year figure at $5.7 billion, down 7.57% from the prior year.
• Total Non-Current Liabilities was $100.9 billion for Q2 2026 at Pfizer, down from $103.0 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $113.4 billion in Q1 2024 and troughed at $5.7 billion in Q4 2025.
• A 5-year average of $71.2 billion and a median of $98.7 billion in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities slipped 9.16% in 2023 and soared 607.25% in 2024, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $6.0 billion in 2022, then advanced by 0.03% to $6.0 billion in 2023, then advanced by 3.45% to $6.2 billion in 2024, then slipped by 7.57% to $5.7 billion in 2025, then jumped by 1658.66% to $100.9 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $100.9 billion (Q2 2026), $103.0 billion (Q1 2026), and $5.7 billion (Q4 2025), per Business Quant data.